AstraZeneca Medicines  Medicines AstraZeneca Medicines  Medicines
  • Home
  • Cardiovascular
  • Diabetes
  • Oncology
    • Oncology
    • Lynparza (olaparib)
      • Lynparza (olaparib)
      • About Lynparza (olaparib) in Ovarian Cancer
      • PAOLA-1
      • SOLO-1
      • Platinum-sensitive Relapsed Setting
      • Safety Information
      • Training and Resources
      • References
    • Imfinzi ▼ (durvalumab)
      • Imfinzi ▼ (durvalumab)
      • IMFINZI (NSCLC)
        • IMFINZI (NSCLC)
        • About stage III NSCLC
        • MOA
        • Efficacy
        • PD-L1 TESTING
        • SAFETY PROFILE
        • Dosing
        • Interactive Case Studies
        • Supporting Materials
      • IMFINZI (ES-SCLC)
        • IMFINZI (ES-SCLC)
        • Disease State
        • Efficacy
        • SAFETY
        • DOSING
        • Supporting Materials
    • Zoladex (goserelin)
      • Zoladex (goserelin)
      • Prescribing Information
        • Prescribing Information
        • Indications & Usage
      • Administration
      • Patient information leaflets and materials
    • HRD Testing
      • HRD Testing
      • HRD testing
        • HRD testing
        • Introduction
        • What is HRD?
        • Why is HRD testing important in advanced ovarian cancer?
        • When to test advanced ovarian cancer patients?
        • Who to test for HRD?
        • How to HRD test?
        • How long will it take to receive the results?
        • What are the sample requirements for HRD testing?
        • Lynparza maintenance treatment options
      • References
  • Haematology
  • Respiratory
    • Respiratory
    • Symbicort Asthma (budesonide/formoterol)
      • Symbicort Asthma (budesonide/formoterol)
      • The Turbohaler device
      • Product information
        • Product information
        • Therapeutic indications & presentation
      • Over-reliance on SABAs
      • Meet Sam
      • Symbicort Maintenance and Reliever Therapy
      • Prescribing Symbicort
      • Safety and tolerability
      • Resources
      • References
      • Home
      • On demand
      • Meetings calendar
  • Supply chain
    • Supply chain
    • Supply of AstraZeneca medicines
    • Supply Requirements Form
    • Our Medicines
    • Supply of Medicines
    • AstraZeneca Customers
    • Contact Supply Chain
    • FAQ
  • Medical Information
  • More Hide
    Imfinzi™ (durvalumab)
    AstraZeneca Medicines Medicines
    Back to top

    Thank you for visiting the AstraZeneca Medicines website

    This link will take you to a website not owned by AstraZeneca. AstraZeneca provides this link as a service to our site visitors. AstraZeneca are not responsible for the content or privacy / legal policies of any third party websites.

    Do you wish to continue?

    Cancel Continue

    Thank you for visiting the AstraZeneca Medicines website

    This link will take you to a website not owned by AstraZeneca. AstraZeneca provides this link as a service to our site visitors. AstraZeneca are not responsible for the content or privacy / legal policies of any third party websites.

    Do you wish to continue?

    Cancel Continue
     

    Validating...

    Welcome to AstraZeneca Medicines UK

    The content on this website is intended for UK Healthcare Professionals only. The website contains both promotional and non-promotional content.

    I am not a UK Healthcare Professional

    Welcome to the AstraZeneca Medicines Site

    Sorry, your web browser is not supported

    Unfortunately, you are using an unsupported browser. Please use Google Chrome 52.0 or Internet Explorer 11 or later. Apologies for any inconvenience.

    GB-6911 - June 2017

    Cancel

    AstraZeneca Medicines

    This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk. 

    Additional Info


    • Legal Notice and Terms of Use
    • Privacy Notice
    • Cookie Policy
    • Site Map

    Contact AstraZeneca


    • Contact Us
    • Report Adverse Event

    Adverse events should be reported. Reporting forms and information can be found at  www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com or by calling 0800 783 0033.

    © AstraZeneca 2021. All rights reserved. GB-16535 : April 2019
    Back to top